Relevant bibliographies by topics / Fibroblast growth factor binding protein 1

Academic literature on the topic 'Fibroblast growth factor binding protein 1'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Fibroblast growth factor binding protein 1.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Fibroblast growth factor binding protein 1"

1

MIZUKOSHI, Eiichi, Masashi SUZUKI, Alexei LOUPATOV, Takehito URUNO, Hisaki HAYASHI, Tomoko MISONO, Sunil C. KAUL, Renu WADHWA, and Toru IMAMURA. "Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin." Biochemical Journal 343, no. 2 (October 8, 1999): 461–66. http://dx.doi.org/10.1042/bj3430461.

Full text
Abstract:
Fibroblast growth factor-1 (FGF-1), which lacks a signal peptide and is intracellularly localized as a result of endogenous expression or endocytosis, is thought to be involved in regulating cell growth and differentiation. In the study reported here, we purified proteins that bind intracellular FGF-1. Affinity adsorption was used to purify FGF-1-binding proteins from rat L6 cells expressing FGF-1. One of the isolated proteins was identified as the glucose-regulated protein GRP75/mortalin/PBP-74/mthsp70, a member of the hsp70 family of heat-shock proteins known to be involved in regulating glucose responses, antigen processing and cell mortality. The interaction of FGF-1 and GRP75/mortalin in vivo was confirmed by co-immunoprecipitation, immunohistochemical co-localization in Rat-1 fibroblasts and by using the yeast two-hybrid system. Moreover, a binding assay in vitro with the use of recombinant FGF-1 and mortalin demonstrated a direct physical interaction between the two proteins. These results reveal that GRP75/mortalin is an intracellular FGF-1-binding protein in cells and suggest that GRP75/mortalin is involved in the trafficking of and/or signalling by FGF-1.
APA, Harvard, Vancouver, ISO, and other styles
2

Newman, Andrew C., Martin N. Nakatsu, Wayne Chou, Paul D. Gershon, and Christopher C. W. Hughes. "The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for endothelial cell lumen formation." Molecular Biology of the Cell 22, no. 20 (October 15, 2011): 3791–800. http://dx.doi.org/10.1091/mbc.e11-05-0393.

Full text
Abstract:
A role for fibroblasts in physiological and pathological angiogenesis is now well recognized; however, the precise mechanisms underlying their action have not been determined. Using an in vitro angiogenesis model in combination with a candidate gene approach, column chromatography, and mass spectrometry, we identify two classes of fibroblast-derived factors—one that supports vessel sprouting but not lumen formation, and one that promotes lumen formation. In the absence of fibroblasts a combination of angiopoietin-1, angiogenin, hepatocyte growth factor, transforming growth factor-α, and tumor necrosis factor drives robust endothelial cell (EC) sprouting; however, lumens fail to form. Subsequent addition of fibroblast-conditioned medium restores lumenogenesis. Using small interfering RNA–mediated knockdown, we show that five genes expressed in fibroblasts—collagen I, procollagen C endopeptidase enhancer 1, secreted protein acidic and rich in cysteine, transforming growth factor-β–induced protein ig-h3, and insulin growth factor–binding protein 7—are necessary for lumen formation. Moreover, lumen formation can be rescued by addition of purified protein to knockdown cultures. Finally, using rheology, we demonstrate that the presence of these matricellular proteins results in significantly stiffer gels, which correlates with enhanced lumen formation. These findings highlight the critical role that fibroblast-derived extracellular matrix components play in EC lumen formation and provide potential insight into the role of fibroblasts in the tumor microenvironment.
APA, Harvard, Vancouver, ISO, and other styles
3

Desnoyers, Luc, David Arnott, and Diane Pennica. "WISP-1 Binds to Decorin and Biglycan." Journal of Biological Chemistry 276, no. 50 (October 11, 2001): 47599–607. http://dx.doi.org/10.1074/jbc.m108339200.

Full text
Abstract:
Wnt-1-induced secreted protein 1 (WISP-1) is a member of the CCN (connective tissue growth factor,Cyr61,NOV) family of growth factors. Structural and experimental evidence suggests that CCN family member activities are modulated by their interaction with sulfated glycoconjugates. To elucidate the mechanism of action for WISP-1, we characterized the specificity of its tissue and cellular interaction and identified binding factors. WISP-1 binding was restricted to the stroma of colon tumors and to cells with a fibroblastic phenotype. By using a solid phase assay, we showed that human skin fibroblast conditioned media contained WISP-1 binding factors. Competitive inhibition with different glycosaminoglycans and treatment with glycosaminoglycan lyases and proteases demonstrated that binding to the conditioned media was mediated by dermatan sulfate proteoglycans. Mass spectrometric analysis identified the isolated binding factors as decorin and biglycan. Decorin and biglycan interacted directly with WISP-1 and inhibited its binding to components in the conditioned media. Similarly, WISP-1 interaction with human skin fibroblasts was inhibited by dermatan sulfate, decorin, and biglycan or by treatment of the cell surface with dermatan sulfate-specific lyases. Together these results demonstrate that decorin and biglycan are WISP-1 binding factors that can mediate and modulate its interaction with the surface of fibroblasts. We propose that this specific interaction plays a role in the regulation of WISP-1 function.
APA, Harvard, Vancouver, ISO, and other styles
4

Carreras, Isabel, Celeste B. Rich, Julie A. Jaworski, Sandra J. Dicamillo, Mikhail P. Panchenko, Ronald Goldstein, and Judith Ann Foster. "Functional components of basic fibroblast growth factor signaling that inhibit lung elastin gene expression." American Journal of Physiology-Lung Cellular and Molecular Physiology 281, no. 4 (October 1, 2001): L766—L775. http://dx.doi.org/10.1152/ajplung.2001.281.4.l766.

Full text
Abstract:
Previously, we have demonstrated that basic fibroblast growth factor (bFGF) decreases elastin gene transcription in confluent rat lung fibroblasts via the binding of a Fra-1-c-Jun heterodimer to an activator protein-1-cAMP response element in the distal region of the elastin promoter. In the present study, we show that bFGF activates the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2, resulting in the translocation of phosphorylated extracellular signal-regulated kinase 1/2 into the nucleus followed by increased binding of Elk-1 to the serum response element of the c-Fos promoter, transient induction of c-Fos mRNA, and sustained induction of Fra-1 mRNA. The addition of PD-98059, an inhibitor of mitogen-activated protein kinase kinase, abrogates the bFGF-dependent repression of elastin mRNA expression. Comparative analyses of confluent and subconfluent fibroblast cultures reveal significant differences in elastin mRNA levels and activator protein-1 protein factors involved in the regulation of elastin transcription. These findings suggest that bFGF modulates specific cellular events that are dependent on the state of the cell and provide a rationale for the differential responses that can be expected in development and injury or repair situations.
APA, Harvard, Vancouver, ISO, and other styles
5

Briones, Victorino R., Shiyou Chen, Anna Tate Riegel, and Robert J. Lechleider. "Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-β." Biochemical and Biophysical Research Communications 345, no. 2 (June 2006): 595–601. http://dx.doi.org/10.1016/j.bbrc.2006.04.052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Caccia, P., O. Cletini, A. Isacchi, L. Bergonzoni, and G. Orsini. "Biochemical characterization of the molecular interaction between recombinant basic fibroblast growth factor and a recombinant soluble fibroblast growth factor receptor." Biochemical Journal 294, no. 3 (September 15, 1993): 639–44. http://dx.doi.org/10.1042/bj2940639.

Full text
Abstract:
The extracellular domain of human fibroblast growth factor receptor (XC-FGF-R) was expressed in Escherichia coli. The protein was purified to homogeneity and the interaction with basic fibroblast growth factor (bFGF), its physiological ligand, was examined. Using resins on which bFGF was reversibly bound, we analysed the characteristics of the binding between XC-FGF-R and immobilized bFGF. We also investigated the stoichiometry of the binding between XC-FGF-R and recombinant human bFGF (rhbFGF) applying non-denaturing gel electrophoresis, chemical cross-linking followed by SDS/PAGE, and gel-filtration chromatography. In cross-linking and gel-filtration chromatography experiments, a 1:1 complex between rhbFGF and XC-FGF-R was observed. The complex was separated from the non-complexed proteins using non-denaturing PAGE in the presence of 0.1% Triton X-100. The band corresponding to the complex was recognized by specific antibodies directed against bFGF and its receptor, blotted on poly(vinylidene difluoride) membranes and submitted to sequence and amino acid analysis. The data obtained from these determinations confirmed the formation of a 1:1 complex between rhbFGF and XC-FGF-R.
APA, Harvard, Vancouver, ISO, and other styles
7

Prakash, S., and D. J. Wyler. "Fibroblast stimulation in schistosomiasis. XII. Identification of CD4+ lymphocytes within schistosomal egg granulomas as a source of an apparently novel fibroblast growth factor (FsF-1)." Journal of Immunology 148, no. 11 (June 1, 1992): 3583–87. http://dx.doi.org/10.4049/jimmunol.148.11.3583.

Full text
Abstract:
Abstract Granulomas that form around Schistosoma mansoni eggs deposited in the liver secrete a variety of fibrogenic factors that may provide a molecular link between chronic inflammation and hepatic fibrogenesis in schistosomiasis. We recently isolated from conditioned medium of egg granuloma cultures a approximately equal to 60-kDa heparin-binding growth factor for fibroblasts. Because this protein is distinct from other defined heparin-binding growth factors, we designated it "fibroblast stimulating factor-1" (FsF-1). We now report that FsF-1 is a lymphokine. We prepared IgG antibody against purified FsF-1 and determined that it did not cross-react with a variety of growth factors or recombinant interleukins. Using two-color flow cytometry of dissociated granuloma cell suspensions, we observed that approximately 20% to 25% of granuloma CD4+ lymphocytes express surface FsF-1. We isolated CD4+ granuloma lymphocytes by FACS and observed that these cells spontaneously secrete into culture supernatant a fibroblast mitogen that is neutralized by anti-FsF-1 antibody. Furthermore, anti-FsF-1 can specifically immunoprecipitate a metabolically labeled protein produced by the granuloma CD4+ lymphocytes. The labeled protein has the same apparent molecular mass (approximately equal to 60 kDa) as FsF-1 purified from granuloma culture supernatants. These findings define CD4+ lymphocytes as a source of FsF-1. Because FsF-1 has biologic and chemical features distinct from most other defined lymphokines and from other heparin-binding growth factors, FsF-1 appears to be a novel lymphokine.
APA, Harvard, Vancouver, ISO, and other styles
8

Taipale, J., J. Saharinen, K. Hedman, and J. Keski-Oja. "Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils." Journal of Histochemistry & Cytochemistry 44, no. 8 (August 1996): 875–89. http://dx.doi.org/10.1177/44.8.8756760.

Full text
Abstract:
We studied the localization of latent transforming growth factor-beta 1 (TGF-beta 1) and its binding protein (LTBP-1) in the extracellular matrix of cultured human fibroblasts by immunofluorescence and immunoelectron microscopy. Immunofluorescence of confluent fibroblast cultures indicated that LTBP-1 localizes to extracellular fibrillar structures resembling fibronectin-collagen matrix. Similar fibrillar structures were detected in cells stained with antibodies specific for TGF-beta 1 propeptide (beta 1-LAP). Both LTBP-1 and beta 1-LAP colocalized with fibronectin in double immunofluorescence analysis. These fibrillar structures were resistant to extraction with sodium deoxycholate, which is further evidence that LTBP-1 and large latent TGF-beta 1 complexes are integral components of the extracellular matrix. SV-40-transformed human fibroblasts lacked extracellular LTBP-1 fibers. EM analysis revealed approximately 10-nm-thick microfibrils that were labeled by anti-LTBP at 90-140-nm intervals. In addition, LTBP-1 was found in structures that were heavily labeled for fibronectin. The accumulation of LTBP-1 in the fibronectin matrix could be reconstituted in vitro. When isolated matrix components were immobilized on nitrocellulose and incubated with fibroblast conditioned medium, LTBP-1 from the medium associated with cellular fibronectin but not with heparan or chondroitin sulfate, vitronectin, tenascin, laminin, or collagen I or IV. The association of LTBP-1 with cellular fibronectin was abolished by treatment of the medium with plasmin, which cleaves LTBP-1 and inhibits its assembly to matrix. The present results indicate that latent TGF-beta 1 complexes are components of the extracellular matrix and suggest that alterations of the pericellular matrix could result in aberrant TGF-beta signaling.
APA, Harvard, Vancouver, ISO, and other styles
9

Fang, Xiaohong, Ewa K. Stachowiak, Star M. Dunham-Ems, Ilona Klejbor, and Michal K. Stachowiak. "Control of CREB-binding Protein Signaling by Nuclear Fibroblast Growth Factor Receptor-1." Journal of Biological Chemistry 280, no. 31 (May 31, 2005): 28451–62. http://dx.doi.org/10.1074/jbc.m504400200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shintani, Tomoaki, Mirai Higaki, and Tetsuji Okamoto. "Heparin-Binding Protein 17/Fibroblast Growth Factor-Binding Protein-1 Knockout Inhibits Proliferation and Induces Differentiation of Squamous Cell Carcinoma Cells." Cancers 13, no. 11 (May 29, 2021): 2684. http://dx.doi.org/10.3390/cancers13112684.

Full text
Abstract:
Heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) has been observed to induce the tumorigenic potential of epithelial cells and is highly expressed in oral cancer cell lines and tissues. It is also recognized as a pro-angiogenic molecule because of its interaction with fibroblast growth factor (FGF)-2. In this study, we examined the functional role of HBp17/FGFBP-1 in A431 and HO-1-N-1 cells. Originally, HBp17/FGFBP-1 was purified from A431 cell-conditioned media based on its capacity to bind to FGF-1 and FGF-2. We isolated and established HBp17/FGFBP-1-knockout (KO)-A431 and KO-HO-1-N-1 cell lines using the clusters of regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) gene editing technology. The amount of FGF-2 secreted into conditioned medium decreased for A431-HBp17-KO and HO-1-N-1-HBp17-KO cells compared to their WT counterparts. Functional assessment showed that HBp17/FGFBP-1 KO inhibited cell proliferation, colony formation, and cell motility in vitro. It also inhibited tumor growth in vivo compared to controls, which confirmed the significant difference in growth in vitro between HBp17-KO cells and wild-type (WT) cells, indicating that HBp17/FGFBP-1 is a potent therapeutic target in squamous cell carcinomas (SCC) and oral squamous cell carcinomas (OSCC). In addition, complementary DNA/protein expression analysis followed by Gene Ontology and protein–protein interaction (PPI) analysis using the Database for Visualization and Integrated Discovery and Search Tool for the Retrieval of Interacting Genes/Proteins showed that both gene and protein expression related to epidermal development, cornification, and keratinization were upregulated in A431-HBp17-KO and HO-1-N-1-KO cells. This is the first discovery of a novel role of HBp17/FGFBP-1 that regulates SCC and OSCC cell differentiation.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Fibroblast growth factor binding protein 1"

1

Baker, Tabari M. "Regulation of microRNAs targeting the angiogenic switch molecule Fibroblast Growth Factor Binding Protein 1 by retinoic acid receptor activation." Thesis, Georgetown University, 2014. http://pqdtopen.proquest.com/#viewpdf?dispub=3618988.

Full text
Abstract:

This dissertation examines the role of retinoic acid receptor activation in the post-transcriptional regulation of a fibroblast growth factor binding protein. Previous work showed that all-trans retinoic acid (ATRA) reduces mRNA expression of the angiogenic switch molecule, Fibroblast Growth Factor Binding Protein 1 (FGFBP1 or FGF-BP), independent of an effect on transcription of the FGFBP1 mRNA. I hypothesized that a retinoid-induced microRNA was involved in FGFBP1 mRNA loss. MicroRNAs (miRs) are 19-22 nucleotide (nt) single stranded non-coding RNAs that post-transcriptionally repress mature mRNA function, thereby reducing expression of their target proteins. The current dogma suggests that miRs canonically bind to the 3' untranslated region (UTR) of mRNA through a 7-nt seed-matched site. However, recent data indicate that miRs may also bind the open reading frame (ORF) of mRNAs. In this dissertation, I show that miR-27b-3p and miR-125a-5p are induced by ATRA and target FGFBP1. Overexpression of miR-27b-3p and miR-125a-5p rapidly reduced FGFBP1 mRNA levels through a target site in the open reading frame of the FGFBP1 mRNA. Both microRNAs showed specificity for regions within the ORF of FGFBP1, suggesting that these microRNAs may also be involved in inhibiting translation of the FGFBP1 protein. Next generation sequencing data from The Cancer Genome Atlas shows that loss of these microRNAs is characteristic of several epithelial cancers, including head and neck, lung, and cervical squamous cell carcinomas, suggesting a tumor suppressor role for miRs 27a-3p and 125a-5p. In total, these data suggest an important regulatory role for miRs 27b-3p and 125a-5p in the oncogenesis of squamous cell carcinomas, through modulation of FGFBP1 expression.

APA, Harvard, Vancouver, ISO, and other styles
2

Yateman, Martin Edward. "Regulation of human fibroblast insulin-like growth factor (IGF)-binding proteins by IGF-1 and cytokines, mechanisms of action and effects upon IGF bioactivity." Thesis, Queen Mary, University of London, 1995. http://qmro.qmul.ac.uk/xmlui/handle/123456789/1742.

Full text
Abstract:
The insulin-like growth factors, IGF-I and IGF-II, are ubiquitous polypeptide molecules that have mitogenic and metabolic actions in a wide variety of cell types, and consequently play a major role in mammalian growth and development. Unlike many other peptide hormones, IGF levels and their bioactivity are highly dependent upon the secretion of a family of six specific binding proteins, named IGFBPs. In this thesis, we have developed a normal human fibroblast in vitro cell culture model to investigate both factors that affect IGFBP secretion, the mechanisms behind such regulation, and also the effect of IGFBP modulation upon subsequent IGF-I mitogenic activity. Firstly, we have examined the possible role that the recently discovered IGFBP proteases may have in determining the effect of IGF-I on IGFBP-3 abundance in fibroblast conditioned media. We show that IGF-I increased IGFBP-3 when assessed by ligand blotting, but did not increase immunoreactive IGFBP-3, a discrepancy that could be explained by further data showing an inhibitory effect of IGF-I on the activity of the fibroblast IGFBP-3 protease. Thus, IGF-I protection of IGFBP-3 from enzymatic degradation may help explain the post-transcriptional, non-receptor mediated 'stimulation' of IGFBP-3 by IGF-I in these cells. We also show for the first time the ability of a number of cytokines to regulate IGFBP secretion, perhaps indicating a novel pathway of communication between these immune cell molecules and the IGFs. The inflammatory cytokine interleukin 113(] L-16) inhibited Hs68 fibroblast IGFBP-3 secretion by down-regulating its gene expression, whilst tumour necrosis factor oc (TNF(x) had a similar inhibitory effect on IGFBP-3 and IGFBP-4 but acted via a post-transcriptional mechanism. The exact nature of the TNF(x effect remains to be determined as no evidence was found to suggest TNF(x increased IGFBP protease activity, or that TNF(x removed IGFBPs from the conditioned media by increasing the proportion immobilised on the cell surface. The inhibition of IGFBP secretion by TNF(x was observed to have marked effects upon the mitogenic activity of IGF-I in these cells, with a five-fold increase in sensitivity to the growth factor seen in a novel cytochemical bioassay. 1 Inhibition of fibroblast IGFBP secretion appeared to be restricted to certain cytokines as IL-6 had no effect, whilst high doses of interferon gamma abolished the TNF(X effect. Conversely, transforming growth factor 6 (TGFB) directly stimulated fibroblast IGFBP-3 secretion, via an increase in gene expression, and subsequently resulted in the reduction in the mitogenic activity of IGF-I. These data indicate that a variety of mechanisms can be employed by a number of factors to elicit changes in fibroblast IGFBP secretion, and that these changes may have direct consequencesin determining IGF-I bioactivity. Such is the importance given to the IGFs in maintaining normal somatic growth, changes in IGFBP secretion may contribute to the altered cellular growth and metabolism seen associated with cytokines in conditions as diverse as chronic infection, rheumatoid arthritis, cancer and the wound healing process.
APA, Harvard, Vancouver, ISO, and other styles
3

Gillies, Peter John. "Modulation of dermal microvascular endithelial cell responses to growth factors and haemostatic factors in the presence of vitronectin." Thesis, Queensland University of Technology, 2008. https://eprints.qut.edu.au/37176/1/Peter_Gillies_Thesis.pdf.

Full text
Abstract:
In order to effect permanent closure in burns patients suffering from full thickness wounds, replacing their skin via split thickness autografting, is essential. Dermal substitutes in conjunction with widely meshed split thickness autografts (+/- cultured keratinocytes) reduce scarring at the donor and recipient sites of burns patients by reducing demand for autologous skin (both surface area and thickness), without compromising dermal delivery at the wound face. Tissue engineered products such as Integra consist of a dermal template which is rapidly remodelled to form a neodermis, at which time the temporary silicone outer layer is removed and replaced with autologous split thickness skin. Whilst provision of a thick tissue engineered dermis at full thickness burn sites reduces scarring, it is hampered by delays in vascularisation which results in clinical failure. The ultimate success of any skin graft product is dependent upon a number of basic factors including adherence, haemostasis and in the case of viable tissue grafts, success is ultimately dependent upon restoration of a normal blood supply, and hence this study. Ultimately, the goal of this research is to improve the therapeutic properties of tissue replacements, through impregnation with growth factors aimed at stimulating migration and proliferation of microvascular endothelial cells into the donor tissue post grafting. For the purpose of my masters, the aim was to evaluate the responsiveness of a dermal microvascular endothelial cell line to growth factors and haemostatic factors, in the presence of the glycoprotein vitronectin. Vitronectin formed the backbone for my hypothesis and research due to its association with both epithelial and, more specifically, endothelial migration and proliferation. Early work using a platform technology referred to as VitroGro (Tissue Therapies Ltd), which is comprised of vitronectin bound BP5/IGF-1, aided keratinocyte proliferation. I hypothesised that this result would translate to another epithelium - endothelium. VitroGro had no effect on endothelial proliferation or migration. Vitronectin increases the presence of Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) receptors, enhancing cell responsiveness to their respective ligands. So, although Human Microvascular Endothelial Cell line 1 (HMEC-1) VEGF receptor expression is generally low, it was hypothesised that exposure to vitronectin would up-regulate this receptor. HMEC-1 migration, but not proliferation, was enhanced by vitronectin bound VEGF, as well as vitronectin bound Epidermal Growth Factor (EGF), both of which could be used to stimulate microvascular endothelial cell migration for the purpose of transplantation. In addition to vitronectin's synergy with various growth factors, it has also been shown to play a role in haemostasis. Vitronectin binds thrombin-antithrombin III (TAT) to form a trimeric complex that takes on many of the attributes of vitronectin, such as heparin affinity, which results in its adherence to endothelium via heparan sulfate proteoglycans (HSP), followed by unaltered transcytosis through the endothelium, and ultimately its removal from the circulation. This has been documented as a mechanism designed to remove thrombin from the circulation. Equally, it could be argued that it is a mechanism for delivering vitronectin to the matrix. My results show that matrix-bound vitronectin dramatically alters the effect that conformationally altered antithrombin three (cATIII) has on proliferation of microvascular endothelial cells. cATIII stimulates HMEC-1 proliferation in the presence of matrix-bound vitronectin, as opposed to inhibiting proliferation in its absence. Binding vitronectin to tissues and organs prior to transplant, in the presence of cATIII, will have a profound effect on microvascular infiltration of the graft, by preventing occlusion of existing vessels whilst stimulating migration and proliferation of endothelium within the tissue.
APA, Harvard, Vancouver, ISO, and other styles
4

Montenegro, Luciana Ribeiro. "Estudo in vitro da sensibilidade ao IGF-1 de fibroblastos de crianças nascidas pequenas para a idade gestacional sem recuperação estatural pós-natal." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5135/tde-08092009-132008/.

Full text
Abstract:
Introdução: Crianças nascidas pequenas para a idade gestacional (PIG) apresentam maior risco de permanecerem com baixa estatura na vida adulta. Os fatores de crescimento insulino-símile tipo 1 e 2 (IGF-1 e IGF-2) são os principais fatores endócrinos determinantes do crescimento fetal. A maioria das ações conhecidas do IGF-1 e 2 é mediada via um receptor tirosina quinase, conhecido como IGF-1R. Recentemente, a insensibilidade ao IGF-1 foi identificada como uma das causas de retardo de crescimento em crianças nascidas PIG que não apresentaram recuperação espontânea do crescimento na vida pós-natal. Crianças afetadas apresentavam níveis elevados de IGF-1, IGFBP-3 além de microcefalia. O papel de defeitos pósreceptor na sinalização do IGF-1 como causa de retardo de crescimento pré e pós-natal ainda não foi investigado. Objetivo: Analisar in vitro a ação do IGF-1 em fibroblastos de crianças nascidas PIG. Material e métodos: Desenvolvemos cultura de fibroblastos de 2 controles (C1 e C2) e de 4 pacientes nascidos PIG (SGA1, SGA2, SGA3 e SGA4) com suspeita de insensibilidade ao IGF-1 por ausência de recuperação do crescimento na vida pós natal, resposta insatisfatória ao tratamento com hGH apesar de níveis normais/elevados de IGF-1. Foi confirmado do ponto de vista molecular que um dos pacientes (SGA1) apresenta Síndrome de Sílver- Russell com perda da metilação do alelo paterno da região ICR1 (imprinting center region 1) importante para a expressão do IGF-2. Defeitos no gene do IGF1 e IGF1R foram afastados por sequenciamento direto. As ações do IGF- 1 foram determinadas por ensaios de proliferação, análise da produção de IGFPB-3 em meio de cultura e estudos de fosforilação de proteínas da via de sinalização do IGF-1 em fibroblastos (AKT e ERK). Resultados: As linhagens SGA1, SGA2 e SGA3 proliferaram respectivamente 31%, 60% e 78% a menos sob estímulo de IGF-1 em relação ás linhagens controles. Já a linhagem SGA4 apresentou comportamento semelhante ás linhagens controles. No estudo da expressão do RNAm do IGF1R por PCR em tempo real, não foi observada diferença significativa na expressão do IGF1R nas diversas linhagens PIG em relação aos controles, assim como o conteúdo total da proteína IGF-1R. Em relação á ativação da via MAPK, todas as linhagens dos pacientes PIGs apresentaram menor fosforilação ERK1/2 basal e após estímulo com IGF-1, quando comparadas com as linhagens controles (p < 0.001) apesar do conteúdo total de ERK1/2 ser semelhante. Já em relação a ativação da via PI3K, as linhagens SGA1, SGA2, SGA3 e SGA4 não diferiram significantemente em relação aos fibroblastos controles quanto à ativação de AKT pelo IGF-1. O conteúdo total de AKT também foi semelhante em todas as linhagens estudadas. O estudo da expressão de IGFBP3 mostrou um aumento da expressão deste peptídeo na linhagem de fibroblastos do paciente SGA1 (14X). O conteúdo de IGFBP-3 intracelular não sofreu alteração, porém comprovamos que a linhagem SGA1 secretava 2x mais IGFBP-3 para o meio de cultura. Apesar de apresentarem estrutura, expressão e conteúdo de IGF1R normais, essas mesmas 3 linhagens celulares que apresentaram menor proliferação também apresentaram diminuição na fosforilação de ERK após tratamento com IGF-1. Mesmo sob o estímulo com desIGF-1 (um análogo do IGF-1 com baixa afinidade por IGFBPs mas que preserva sua capacidade de ativar o receptor IGF-1R) a ativação de ERK e a proliferação celular se manteve abaixo dos das linhagens controles. O estudo do conteúdo total de GRB10 foi semelhante em todas as linhagens celulares. Conclusão: Três dos 4 pacientes PIG estudados apresentaram insensibilidade pós-receptor ao IGF-1. A linhagem celular SGA1, obtida de um paciente com hipometilação do ICR1 11p15 causando SSR, demonstramos um aumento da expressão e secreção de IGFBP-3, o qual não se mostrou responsável por inibir a ação do IGF-1 nestes fibroblastos. Novos estudos devem ser desenvolvidos para identificar o defeito molecular responsável pela insensibilidade ao IGF-1 a nível pósreceptor observada nestes pacientes.
Introduction: Children born small for gestational age (SGA) have a higher risk of staying with short stature in adulthood. The insulin-like growth factors (IGF-1 and IGF-2) are the main endocrine factor determining fetal growth. Most of the known actions of IGFs are mediated by IGF-1R, a tyrosine kinase receptor. Recently, the IGF-1 insensitivity was identified causing growth retardation in children born SGA who who did not present spontaneous catch-up growth in postnatal life. Affected children had elevated IGF-1 and IGFBP-3 levels in addition to microcephaly. The role of post receptor defects in IGF-1 signaling on the deficit of growth is still unclear. Objective: To assess IGF-1 action and signaling in vitro in fibroblasts from SGA children. Methods: Fibroblasts cell cultures were developed from 2 controls (C1 and C2) and 4 patients with pre- and post-natal growth retardation (SGA1, SGA2, SGA3 and SGA4). IGF-1 insensitivity was demonstrated by severe pre and postnatal growth impairment without any evident cause, IGF1 SDS > 0 and poor growth response during high doses of hGH treatment. Three SGA patients presented microcephaly. Defects in the gene of the IGF1 and IGF1R were excluded by direct sequencing. One patient (SGA1) presents the Silver- Russell syndrome (SRS) with loss of methylation of the paternal allele in the ICR1 (imprinting center region 1) chromosome 11p15, important for IGF-2 expression. IGF-1 action was assessed by cell proliferation by colorimetric assay. IGF-1 signaling was assessed by AKT and ERK phosphorylation after IGF-1 stimulation through SDS-PAGE of intracellular extract followed by immunoblotting with specific antibodies. The expression of IGF1R and IGFBP3 gene was determined by Real-time quantitative PCR and the levels of the IGF-1R and IGBP-3 protein by direct immunoblotting. Results: The SGA1, SGA2 and SGA3 cell lines proliferated 31%, 60% and 78% less under IGF-1 stimulation in comparison of controls fibroblasts, respectively. The expression of IGF1R mRNA and the level of total amount of IGF-1R protein were similar in all SGA and control cell lines. Despite normal IGF-1R structure and quantity, the same 3 SGA cell lines that presented low proliferation response also had 50 to 85% lower ERK phosphorylation after IGF-1 treatment (p <0.001), although the similar total content of ERK1/2. In relation to PI3K pathway activation, all SGA cell cultures presented normal AKT phosphorilation. Fibroblasts from the SGA1 patient presented a 14x increase in IGFBP3 mRNA and 2x more IGFBP-3 secretion to culture serum medium. Treatment with desIGF-1, an IGF-1 analogue with low affinity for IGFBPs although retains its ability to activate the IGF-1R, did not recover cell proliferation or ERK phosphorylation. All cell lines presented similar amount of GRB10 protein Conclusion: Three of 4 SGA patients showed evidence of post-receptor IGF-1 insensitivity. The cell line SGA1, obtained from a SRS patient with ICR1 hypomethylation, showed increased expression and secretion of IGFBP-3, which was not directly responsible for inhibition in IGF- 1 action. Further studies should be developed to identify the molecular cause of IGF-1 post-receptor insensitivity observed in our patients.
APA, Harvard, Vancouver, ISO, and other styles
5

Marshall, Nicholas John. "The influence of insulin-like growth factor 1 and its analogues on fibroblasts and dermal wound healing." Title page, table of contents and synopsis only, 1998. http://web4.library.adelaide.edu.au/theses/09MD/09mdm3685.pdf.

Full text
Abstract:
Includes bibliography (leaves 191-219). Examines the levels of insulin-like growth factor and the presence of IGF binding proteins in human wound fluid. Tests the potency of IGF-1 and 2 analogues in in vitro models of fibroblast activity and their effect on healing in normal and diabetic rodent wounds. Shows that IGF-1, IGF-2 and their binding proteins are present in fluid from a partial thickness cutaneous wound; that the binding proteins negatively modulate the activity of insulin-like growth factors in vitro, but that the IGFs do not necessarily show enhanced activity in vivo at the wound site if binding protein affinity is decreased. Discusses possible roles of these binding proteins in wound repair.
APA, Harvard, Vancouver, ISO, and other styles
6

Martin, Christopher School of Biomedical Engineering UNSW. "Investigation of exogenous growth factors; platelet derived growth factor, insulin-like growth factor binding protein and fibroblast growth factor, and their influence on in vivo bone repair." Awarded by:University of New South Wales. School of Biomedical Engineering, 2006. http://handle.unsw.edu.au/1959.4/30405.

Full text
Abstract:
This research investigated if exogenous growth factors (GFs), in particular platelet derived growth factor (PDGF), has an in vivo effect on the healing response of normal healthy bone. The research was orientated to study whether a clinical beneficial effect could be demonstrated. To achieve this two animal models were utilised, namely, a rabbit tibial osteotomy model and an ovine tibial defect and porous implant ingrowth model. The rabbit model comprised of a unilateral V-shaped tibial osteotomy, stabilised with an absorbable intramedullary pin and figure-of-eight tension band suture, with a 3 week survival period. The GFs tested in this model were 3 concentrations of PDGF, a single dose of insulin-like growth factor binding protein (IGF-BP) and a combination of the two. Each osteotomy was injected with a single bolus of collagen (control) or collagen containing GF (treatment) during surgery. After sacrifice tibiae were CT-scanned in situ, harvested and subject to 4-point bend testing. The callus, underlying bone and contralateral bone's greyscales and mechanical testing results were used for comparative analysis. The ovine model consisted of implanting 6 small rectangular shaped titanium alloy porous implants and one empty defect bilaterally in sheep's tibiae, for 4 and 6 weeks. The sheep were injected with tetracycline bone marker at 2 week intervals. The model's characteristics and any positional effects were initially investigated. Followed by an investigation into the influence of various exogenous GFs on the healing response and ingrowth characteristics of bone into the porous implants. The GFs investigated were PDGF, IGF-BP and fibroblast growth factor impregnated into the porous implants in a collagen carrier. Comparative analysis was done on results from 3-point bend testing of the bone/implant interface, image analysis to quantify percentage of bone, from scanning electron microscopy images of implant sections and confocal microscopy images of tibial defect sections. Analyses indicate that the GFs investigated have a direct and quantifiable positive in vivo effect. The more significant finding is that the growth factors have a potent systemic effect. These results were confirmed by both the sheep porous bone plug model and the rabbit tibial osteotomy model used within this research.
APA, Harvard, Vancouver, ISO, and other styles
7

Paripelly, Rammohan. "Molecular Level Interaction of Human Fibroblast Growth Factor-1 (hFGF-1) With Phloridzin." TopSCHOLAR®, 2013. http://digitalcommons.wku.edu/theses/1314.

Full text
Abstract:
Fibroblast growth factors (FGFs) are a family of growth factors which includes twenty three proteins. FGFs work as modulators for various cellular activities like mitosis, differentiation and survival. Among the FGF family, human fibroblast growth factor-1 (hFGF-1), which is also known as acidic fibroblast growth factor, is a potent angiogenic agent, involved in the formation of new blood vessels in various tissues. hFGF-1 is regarded as a prototype of the FGF family. It serves as one of the potential targets in tumor inhibition and obesity due to its involvement in new blood vessel formation in cancerous regions and adipose tissues. In general, FGFs exert their action by binding to heparin, forming FGF-heparin complex, which can then bind to fibroblast growth factor receptors (FGFRs). Inhibition of FGF dependent signal transduction by heparin mimicking compounds has shown promising results in control and treatment of tumor growth. Naturally occurring glycoside called phloridzin found to have anticancer property. Phloridzin (2-glucoside of phloretin) has structural resemblance to heparin; it is a natural antioxidant, widely known for its antidiabetic activity, besides controlling tumor growth. Phloridzin can mimic heparin and compete with it for FGF binding. This binding can be agonistic or antagonistic in nature on FGF signal transduction. In the present study, we investigated the molecular level interaction between phloridzin and hFGF-1 using various biophysical techniques like steady state fluorescence, limited trypsin digestion and protein-NMR spectroscopy. hFGF-1 needed for the study was expressed in recombinant Escherichia coli cells. The expressed protein was then purified using heparin sepharose affinity chromatography. Both expression and purification were monitored using SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Conformational stability of purified hFGF-1 was assessed through steady state fluorescence. Purified hFGF-1 is in, its native, properly folded conformation. Interaction studies, such as thermal unfolding and limited trypsin digestion were performed to assess the thermal stability and solvent accessibility of hFGF-1 in the presence of phloridzin respectively. It was found from interaction studies that hFGF-1 in the presence of phloridzin shown increased thermal stability and increased resistance against trypsin digestion. In order to locate the sites of interaction on hFGF-1 surface, a protein-NMR study was performed. Exact sites of interaction of phloridzin on hFGF-1 surface were found. In future, isothermal titration calorimetry will be performed to determine kinetics of the enthalpy change and dissociation constant of phloridzin-hFGF-1 interaction. In vivo studies will also be performed after completion of in vitro studies, which will give an insight about possibility of phloridzin and hFGF-1 interaction under physiological condition
APA, Harvard, Vancouver, ISO, and other styles
8

Hamilton, Fairley. "Regulation of sex hormone binding globulin and insulin-like growth factor binding protein-1." Thesis, University College London (University of London), 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.243549.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Geitgey, Delaney Kate. "Evaluating the role of fibroblast activation protein and fibroblast growth factor 21 in growth hormone-induced adipose tissue fibrosis." Ohio University Honors Tutorial College / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ouhonors1587596581428154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Öklü, Rahmi. "Expression of latent transforming growth factor-β1 binding protein-1 in atherosclerosis." Thesis, University of Cambridge, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.621723.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Fibroblast growth factor binding protein 1"

1

Westwood, Melissa. Biochemical characterisation of insulin-like growth factor binding protein-1. Manchester: University of Manchester, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

C, Baxter R., Gluckman Peter D, and Rosenfeld Ron G, eds. The insulin-like growth factors and their regulatory proteins: Proceedings of the Third International Symposium on Insulin-Like Growth Factors, Sydney, 6-10 February 1994. Amsterdam: Excerpta Medica, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sun, John. The effects of insulin-like growth factor binding protein-1 on pre- and postnatal cardiac morphology and function. 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Baxter, R. C., and Peter D. Gluckman. The Insulin-Like Growth Factors and Their Regulatory Proteins: Proceedings of the Third International Symposium on Insulin-Like Growth Factors, Sydn (International Congress Series). Elsevier Science Pub Co, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Johnston, Michael V. Coffin-Lowry Syndrome. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0057.

Full text
Abstract:
Coffin-Lowry syndrome (CLS) is a relatively rare (1:50,000-100,000 incidence) sex-linked neurodevelopmental disorder that includes severe intellectual disability, dysmorphic features including facial and digital abnormalities, growth retardation, and skeletal changes. Most cases are sporadic with only 20% to 30% of cases having an additional family member. CLS is caused by variable loss of function mutations in the RPS6KA3 gene that maps to Xp22.2 and codes for the hRSK2 S6 kinase that phosphorylates the transcription factor CREB (cAMP response element binding protein) as well as other nuclear transcription factors. Phosphorylated CREB (pCREB) plays a major role in memory formation in fruit flies and mammals by activating specific genes through epigenetic histone acetylation.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Fibroblast growth factor binding protein 1"

1

Seth, John. "Insulin-Like Growth Factor Binding Protein-1." In The Immunoassay Kit Directory, 206. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-1414-1_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bidlingmaier, M. "Insulin-like growth factor binding protein-3." In Lexikon der Medizinischen Laboratoriumsdiagnostik, 1–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_1585-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

McKeehan, Wallace L., Mikio Kan, Jinzhao Hou, Fen Wang, Pamela Adams, and Per-Erik Mansson. "Heparin-Binding (Fibroblast) Growth Factor/Receptor Gene Expression in the Prostate." In Molecular and Cellular Biology of Prostate Cancer, 115–26. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3704-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Conover, Cheryl A., Jay T. Clarkson, Susan K. Durham, and Laurie K. Bale. "Cellular Actions of Insulin-Like Growth Factor Binding Protein-3." In Advances in Experimental Medicine and Biology, 255–66. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2988-0_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Liu, Xiaozhen, Shuiliang Shi, Jun-Hui Chen, Dianqing Wu, Mikio Kan, Yoshiko Myoken, Tetsuji Okamoto, and J. Denry Sato. "Human Fibroblast Growth Factor-Binding Protein HBp17 Enhances the Tumorigenic Potential of Immortalized Squamous Epithelial Cells." In Animal Cell Technology: Basic & Applied Aspects, 343–52. Dordrecht: Springer Netherlands, 2002. http://dx.doi.org/10.1007/978-94-017-0728-2_61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Baxter, Robert C., and Janet L. Martin. "Regulation and Actions of Insulin-Like Growth Factor Binding Protein-3." In Advances in Experimental Medicine and Biology, 125–35. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5949-4_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cuevas, Pedro, Diana Reimers, Fernando Carceller, Fu Xiaobing, and Guillermo Giménez-Gallego. "Loss of Basic Fibroblast Growth Factor of Brain Ependyma in Old Spontaneously Hypertensive Rats." In Cell Signal Transduction, Second Messengers, and Protein Phosphorylation in Health and Disease, 161–67. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-1879-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Drescher, B., W. Zumkeller, H. Lauke, M. Hartmann, and M. S. Davidoff. "Insulin-Like Growth Factor-Binding Protein (IGFBP)-5 in Human Testicular Tubules." In Advances in Experimental Medicine and Biology, 153–54. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5913-9_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rechler, Matthew M., Alexandra L. Brown, Craig C. Orlowski, Yvonne W. H. Yang, Joyce A. Romanus, Lorenzo Chiariotti, and Carmelo B. Bruni. "Characterization and Cloning of a Rat Insulin-Like Growth Factor Binding Protein." In Molecular and Cellular Biology of Insulin-like Growth Factors and Their Receptors, 395–402. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4684-5685-1_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Clemmons, David R. "Insulin-Like Growth Factor Binding Protein Control Secretion and Mechanisms of Action." In Advances in Experimental Medicine and Biology, 113–23. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5949-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Fibroblast growth factor binding protein 1"

1

Baker, J. B., M. P. McGrogan, C. Simonsen, R. L. Gronke, and B. W. Festoff. "STRUCTURE AND PROPERTIES OF PROTEASE NEXIN I." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644765.

Full text
Abstract:
Human foreskin fibroblasts secrete several different serine protease inhibitors which differ in size and protease specificities. These proteins, called protease nexins (PNs) all form SDS-resistant complexes with their protease targets. Fibroblast surface receptors recognize the protease-PN complexes and mediate their delivery to lysosomes. PNI is a 45 kilodalton glycoprotein that rapidly inhibits several arg or lys-specific proteases including trypsin, thrombin, and urokinase (k assoc.∼ 4×l06,∼ 6×105 and ∼ 2×105, m−1s−1 respectively). Like antithrombin III, PNI binds heparin and inhibits thrombin at a vastly accelerated rate in the presence of this glycoaminoglycan. Immunofluorescence studies show that in addition to secreting PNI foreskin fibroblasts carry this inhibitor on their surfaces. PNI cDNA has been cloned and sequenced. A mixed oligonucleotide probe derived from PNI N-terminal sequence was used to probe a foreskin fibroblast cDNA library constructed with λGT10. Identification of PNI cDNAs has been verified by sequencing and by expressing active PNI protein in mammalian cells. The full amino acid sequence of PNI, deduced from cDNA sequencing, is 392 residues long and has 30% homology to antithrombin III. An arg-ser pair 32 residues from the C-terminus of the inhibitor is proposed as the reactive center P1-P1 residues. In the hinge region a lys residue is present in a position occupied by a ginor glu residue in other serpins. PNI mRNA exists in 2 slightly different forms:One (αPNI) yields a thr-arg-ser sequence wherethe other βPNI) yields a thr-thr-gly-ser sequence. The presence of the appropriate splice acceptor sites in the genome indicates that these forms are generated from a single gene by alternative splicing. Expressed aPNI and 0PNI proteins both bind thrombin and urokinase. In foreskin fibroblaststhe α form of PNI mRNA predominates over the β form by about 2:1. In foreskin fibroblast cultures secreted PNI inhibits the mitogenic response to thrombin and regulate secreted urokinase. Purified PNI added to human fibrosarcoma (HT1080) cells inhibitsthe tumor cell-mediated destruction of extracellular matrix and transiently, but dramatically, inhibits tumor cell growth. PNI or PNI-like inhibitors may function at multiple physiological sites. The β form of PNI is virtually identical to a glia-derived neurite promoting factor, the cDNA for which has been recently cloned and sequenced by Gloor et al (1). The neurite outgrowth activity of PNI may result from inhibition of a thrombin-like protease that is associated with neurons, since a number of thrombin inhibitors stimulate neurite extension. Recent immunofluoresence experiments, carried out with D. Hantai (Inserm; Paris) demonstrate that anti-PNI antibody intensely stains neuromuscular synapses. In addition, a PNI-like inhibitor is associated with platelets. At low (0.5 nM <) 125I-thrombin concentrations formation of 125I-thrombin-platelet PNI complexes accounts for most of the specific binding of 125I-thrombin to platelets (2). Although the platelet-associated form of PNI is electrophoretically and immunologically indistinguishable from fibroblast PNI, it does not bind urokinase, suggesting that it may be distinct.(1) Gloor, S., K. Odink, J. Guenther, H. Nick, and D. Monard. (1986) Cell 47:687-693.(2) Gronke, R.S., B.L. Bergman, and J.B. Baker. (1987) J. Biol. Chem. (in press)
APA, Harvard, Vancouver, ISO, and other styles
2

Belin, D., D. Baccino, A. Wohlwend, A. Estreicher, J. Hurate, and J.-D. Vassalli. "A CELLULAR RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN ACTIVATOR." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642957.

Full text
Abstract:
Recent cell biological and biochemical studies on the urokinase-type plasminogen activator (u-PA) have revealed an unsuspected property of this protein: it binds with high affinity and specificity to the plasma membrane of a number of cell types. Hence, while the interaction of tissue-type plasminogen activator (t-PA) with fibrin suggests a preferred role for this enzyme in the maintenance of fluidity of the extracellular milieu, the cellular binding of u-PA results in the focalisation of plasmin generation to the close environment of the cell surface; this appears as an optimal configuration if u-PA is to participate in the enzymatic events required for cell migration.The available information on the cellular binding of u-PA can be summarized as follows:1. Human monocytes-macrophages, monocyte-like cell lines, fibroblasts, and a variety of other cell lines all express u-PA binding sites. The number of u-PA binding sites on a given cell type may vary as a function of the functional state of the cells. In some cases all sites are occupied by “endogenous” u-PA.2. Binding does not require u-PA activity, and prou-PA binds with the same affinity as does the active enzyme.3. The Kd for u-PA binding is between 1 and 10×10-10 M. The binding site appears to be specific for u-PA.4. Binding requires the presence of the A chain of u-PA; the growth factor module of the A chain is involved in this interaction.5. Bound enzyme does not dissociate readily, nor is it rapidly endocytosed; most importantly, it retains catalytic activity.Studies in progress are aimed at further defining the u-PA determinants responsible for binding. In this context it is noteworthy that there is a tight species specificity of binding: human and murine u-PA, for instance, bind only to cells of the homologous species. Characterization of the u-PA binding site suggests that it is an integral membrane protein that includes at least one Mf 50.000 polypeptide chain.In addition to allowing for the peri-cellular focalisation of u-PA catalysed proteolysis, expression of the u-PA binding site provides a mecanism whereby one cell type can acquire membrane-bound u-PA activity following secretion of the (pro)enzyme by another cell population. A striking example of this is the binding of u-PA, synthesized by the epithelial layer of the male genital tract, to the head region of murine spermatozoa.
APA, Harvard, Vancouver, ISO, and other styles
3

Zheng, H., Z. Zhou, and C. Chen. "Krupple-like factor 5 promotes breast cancer proliferation through activating fibroblast growth factor-binding protein transcription." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-4071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Patel, Nisha S., and Alisa Morss Clyne. "A Computational Model of Fibroblast Growth Factor-2 Binding to Isolated and Intact Cell Surface Receptors: Effects of Fibroblast Growth Factor-2 Concentration, Flow and Delivery Mode." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80798.

Full text
Abstract:
Fibroblast growth factor-2 (FGF2) plays an important role in both healthy vascular cell functions and pathogenesis in cancer, atherosclerosis and reduced perfusion in diabetes (1–4). FGF2 therapy and targeted drug delivery have great potential in the treatment of such diseases, but have had little clinical success. FGF2 binding kinetics to heparan sulfate proteoglycan (HSPG) and fibroblast growth factor receptors (FGFR) have been largely studied under static conditions (5), however FGF2 binding to endothelial cells occurs physiologically under fluid flow conditions. Understanding complex FGF2 binding kinetics would enable the development of new anti- and pro-angiogenic therapeutics. We developed a computational model of FGF2 binding to FGFR and HSPG with flow to investigate the effect of fluid flow and FGF2 delivery mode on FGF2 binding to isolated or combined binding sites.
APA, Harvard, Vancouver, ISO, and other styles
5

Ling, L., V. Nurcombe, A. Van Wijnen, and S. Cool. "PO-004 Antibodies targeting the heparin-binding domain of fibroblast growth factor receptor 1 for cancer therapy." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.541.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rice, Megan S., Rulla M. Tamimi, James L. Connolly, Laura C. Collins, Dejun Shen, Michael N. Pollak, Bernard Rosner, Susan E. Hankinson, and Shelley S. Tworoger. "Abstract A68: Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and lobule type in the Nurses' Health Study II." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Oct 22-25, 2011; Boston, MA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1940-6207.prev-11-a68.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhang, Liping, Andrzej Badzio, Theresa Boyle, Xian Lu, Rafal Dziadziuszko, Jacek Jassem, and Fred R. Hirsch. "Abstract 921: Fibroblast growth factor receptor 1 (FGFR1) protein expression and gene copy number in small cell lung cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-921.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ibrahim, YH, J. Hartel, K. La Parra, and D. Yee. "Insulin-like growth factor binding protein-1 (IGFBP-1) targets both the insulin-like growth factor (IGF) and integrin pathways for the inhibition of breast cancer cell motility." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Saksela, O., D. Moscatelli, and D. B. Rifkin. "THE OPPOSING OF BASIC FIBROBLAST GROWTH FACTOR AND TRANSFORMING GROWTH FACTOR BETA ON THE REGULATION OF PLASMINOGEN ACTIVATOR ACTIVITY IN CAPILLARY ENDOTHELIAL CELLS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644660.

Full text
Abstract:
Basic fibroblast growth factor (bFGF), a potent inducer of angio-genesis in vivo, stimulates the production of both the cell-associated and the secreted forms of urokinase-and tissue-type plasminogen activators (PA) in cultured bovine capillary endothelial cells. This stimulation was counteracted by picogram amounts of transforming growth factor beta The stimulatory effect of bFGF was not completely abolished by increasing the amount of TGFb However, the inhibition by TGFb was greatly enhanced if the cells were pretreated for 1-3 hours with TGFb before addition of bFGF, and the inhibition was almost total, if the' preincubationtime with TGFb was 6 hours.Sequential chanqes of serum-containing medium prior to addition ofbFGF also blocked the PA stimulatory effect of bFGF. This inhibitory activity of serum was reduced by incubation of the serum with anti-TGFb-IgG. After pro-longed incubation of cultures treated simultaneously with bFGF' and TGFb, the inhibitory effect of the added bFGF dominated as assayed by PAlevels. TGFbdid not alter the receptor binding of labeled bFGF, nor did a 6 hour pretreatment with TGFb reducethe amount of bound bFGF. The major difference between effects by bFGF and TGFb was thatwhile bFGF effectively enhanced PA-activi-ty expressed by the cells, TGF decreased the amounts of both cell-associated and secreted PA activity by decreasing enzyme production and proenzyme activation. Both bFGF and TGFb increased the secretion of the endothelial type 1 plasminogen activatorinhibitor (PAI 1). The highest concentration of TGFb is found in platelets, and it is known to be released during clot formation. The suppression of PA production by theendothelium by the release of TGFb shouldresult in a decrease in the fibrinolytic activity and promote clot maintenance. In addition, the rapid stimulation of high levels of PAI 1 secretion from the surrounding capillarycells by platelet released TGFb may further suppress fibrinolysis'. The reversabil it.y of theTGFb effect and domination of bFGF stimulation may be important in relation to the subsequentonset of clot lysis or angiogenesis leadino to thrombus reorganization and wound healing.
APA, Harvard, Vancouver, ISO, and other styles
10

Pfaff, Liza E., Brian T. Kalet, Deanna D. Dailey, and Dawn L. Duval. "Abstract A23: Insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) drives growth, metastasis and chemoresistance in human and canine osteosarcoma." In Abstracts: AACR Special Conference: The Translational Impact of Model Organisms in Cancer; November 5-8, 2013; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1557-3125.modorg-a23.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Fibroblast growth factor binding protein 1"

1

Gibby, Krissa. Role of Fibroblast Growth Factor Binding Protein-1 in Mammary Development and Tumorigenesis. Fort Belvoir, VA: Defense Technical Information Center, October 2009. http://dx.doi.org/10.21236/ada525608.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kagan, Benjamin L. Growth Factor Regulation of an Angiogenic Factor, the Fibroblast Growth Factor-Binding Protein (FGF-BP), in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2001. http://dx.doi.org/10.21236/ada398106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kagan, Benjamin L. Growth Factor Regulation of an Angiogenic Factor, the Fibroblast Growth Factor-Binding Protein (FGF-BP), in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2002. http://dx.doi.org/10.21236/ada410065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gross, Jennifer M. Insulin-Like Growth Factor Binding Protein-1 Interacts with Integrins to Inhibit Insulin-Like Growth Factor-Induced Breast Cancer Growth and Migration. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada420347.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Funkenstein, Bruria, and Shaojun (Jim) Du. Interactions Between the GH-IGF axis and Myostatin in Regulating Muscle Growth in Sparus aurata. United States Department of Agriculture, March 2009. http://dx.doi.org/10.32747/2009.7696530.bard.

Full text
Abstract:
Growth rate of cultured fish from hatching to commercial size is a major factor in the success of aquaculture. The normal stimulus for muscle growth in growing fish is not well understood and understanding the regulation of muscle growth in fish is of particular importance for aquaculture. Fish meat constitutes mostly of skeletal muscles and provides high value proteins in most people's diet. Unlike mammals, fish continue to grow throughout their lives, although the size fish attain, as adults, is species specific. Evidence indicates that muscle growth is regulated positively and negatively by a variety of growth and transcription factors that control both muscle cell proliferation and differentiation. In particular, growth hormone (GH), fibroblast growth factors (FGFs), insulin-like growth factors (IGFs) and transforming growth factor-13 (TGF-13) play critical roles in myogenesis during animal growth. An important advance in our understanding of muscle growth was provided by the recent discovery of the crucial functions of myostatin (MSTN) in controlling muscle growth. MSTN is a member of the TGF-13 superfamily and functions as a negative regulator of skeletal muscle growth in mammals. Studies in mammals also provided evidence for possible interactions between GH, IGFs, MSTN and the musclespecific transcription factor My oD with regards to muscle development and growth. The goal of our project was to try to clarify the role of MSTNs in Sparus aurata muscle growth and in particular determine the possible interaction between the GH-IGFaxis and MSTN in regulating muscle growth in fish. The steps to achieve this goal included: i) Determining possible relationship between changes in the expression of growth-related genes, MSTN and MyoD in muscle from slow and fast growing sea bream progeny of full-sib families and that of growth rate; ii) Testing the possible effect of over-expressing GH, IGF-I and IGF-Il on the expression of MSTN and MyoD in skeletal muscle both in vivo and in vitro; iii) Studying the regulation of the two S. aurata MSTN promoters and investigating the possible role of MyoD in this regulation. The major findings of our research can be summarized as follows: 1) Two MSTN promoters (saMSTN-1 and saMSTN-2) were isolated and characterized from S. aurata and were found to direct reporter gene activity in A204 cells. Studies were initiated to decipher the regulation of fish MSTN expression in vitro using the cloned promoters; 2) The gene coding for saMSTN-2 was cloned. Both the promoter and the first intron were found to be polymorphic. The first intron zygosity appears to be associated with growth rate; 3) Full length cDNA coding for S. aurata growth differentiation factor-l I (GDF-II), a closely related growth factor to MSTN, was cloned from S. aurata brain, and the mature peptide (C-terminal) was found to be highly conserved throughout evolution. GDF-II transcript was detected by RT -PCR analysis throughout development in S. aurata embryos and larvae, suggesting that this mRNA is the product of the embryonic genome. Transcripts for GDF-Il were detected by RT-PCR in brain, eye and spleen with highest level found in brain; 4) A novel member of the TGF-Bsuperfamily was partially cloned from S. aurata. It is highly homologous to an unidentified protein (TGF-B-like) from Tetraodon nigroviridisand is expressed in various tissues, including muscle; 5) Recombinant S. aurata GH was produced in bacteria, refolded and purified and was used in in vitro and in vivo experiments. Generally, the results of gene expression in response to GH administration in vivo depended on the nutritional state (starvation or feeding) and the time at which the fish were sacrificed after GH administration. In vitro, recombinantsaGH activated signal transduction in two fish cell lines: RTHI49 and SAFI; 6) A fibroblastic-like cell line from S. aurata (SAF-I) was characterized for its gene expression and was found to be a suitable experimental system for studies on GH-IGF and MSTN interactions; 7) The gene of the muscle-specific transcription factor Myogenin was cloned from S. aurata, its expression and promoter activity were characterized; 8) Three genes important to myofibrillogenesis were cloned from zebrafish: SmyDl, Hsp90al and skNAC. Our data suggests the existence of an interaction between the GH-IGFaxis and MSTN. This project yielded a great number of experimental tools, both DNA constructs and in vitro systems that will enable further studies on the regulation of MSTN expression and on the interactions between members of the GHIGFaxis and MSTN in regulating muscle growth in S. aurata.
APA, Harvard, Vancouver, ISO, and other styles
6

Barg, Rivka, Erich Grotewold, and Yechiam Salts. Regulation of Tomato Fruit Development by Interacting MYB Proteins. United States Department of Agriculture, January 2012. http://dx.doi.org/10.32747/2012.7592647.bard.

Full text
Abstract:
Background to the topic: Early tomato fruit development is executed via extensive cell divisions followed by cell expansion concomitantly with endoreduplication. The signals involved in activating the different modes of growth during fruit development are still inadequately understood. Addressing this developmental process, we identified SlFSM1 as a gene expressed specifically during the cell-division dependent stages of fruit development. SlFSM1 is the founder of a class of small plant specific proteins containing a divergent SANT/MYB domain (Barg et al 2005). Before initiating this project, we found that low ectopic over-expression (OEX) of SlFSM1 leads to a significant decrease in the final size of the cells in mature leaves and fruits, and the outer pericarp is substantially narrower, suggesting a role in determining cell size and shape. We also found the interacting partners of the Arabidopsis homologs of FSM1 (two, belonging to the same family), and cloned their tomato single homolog, which we named SlFSB1 (Fruit SANT/MYB–Binding1). SlFSB1 is a novel plant specific single MYB-like protein, which function was unknown. The present project aimed at elucidating the function and mode of action of these two single MYB proteins in regulating tomato fruit development. The specific objectives were: 1. Functional analysis of SlFSM1 and its interacting protein SlFSB1 in relation to fruit development. 2. Identification of the SlFSM1 and/or SlFSB1 cellular targets. The plan of work included: 1) Detailed phenotypic, histological and cellular analyses of plants ectopically expressing FSM1, and plants either ectopically over-expressing or silenced for FSB1. 2) Extensive SELEX analysis, which did not reveal any specific DNA target of SlFSM1 binding, hence the originally offered ChIP analysis was omitted. 3) Genome-wide transcriptional impact of gain- and loss- of SlFSM1 and SlFSB1 function by Affymetrix microarray analyses. This part is still in progress and therefore results are not reported, 4) Search for additional candidate partners of SlFSB1 revealed SlMYBI to be an alternative partner of FSB1, and 5) Study of the physical basis of the interaction between SlFSM1 and SlFSB1 and between FSB1 and MYBI. Major conclusions, solutions, achievements: We established that FSM1 negatively affects cell expansion, particularly of those cells with the highest potential to expand, such as the ones residing inner to the vascular bundles in the fruit pericarp. On the other hand, FSB1 which is expressed throughout fruit development acts as a positive regulator of cell expansion. It was also established that besides interacting with FSM1, FSB1 interacts also with the transcription factor MYBI, and that the formation of the FSB1-MYBI complex is competed by FSM1, which recognizes in FSB1 the same region as MYBI does. Based on these findings a model was developed explaining the role of this novel network of the three different MYB containing proteins FSM1/FSB1/MYBI in the control of tomato cell expansion, particularly during fruit development. In short, during early stages of fruit development (Phase II), the formation of the FSM1-FSB1 complex serves to restrict the expansion of the cells with the greatest expansion potential, those non-dividing cells residing in the inner mesocarp layers of the pericarp. Alternatively, during growth phase III, after transcription of FSM1 sharply declines, FSB1, possibly through complexing with the transcription factor MYBI serves as a positive regulator of the differential cell expansion which drives fruit enlargement during this phase. Additionally, a novel mechanism was revealed by which competing MYB-MYB interactions could participate in the control of gene expression. Implications, both scientific and agricultural: The demonstrated role of the FSM1/FSB1/MYBI complex in controlling differential cell growth in the developing tomato fruit highlights potential exploitations of these genes for improving fruit quality characteristics. Modulation of expression of these genes or their paralogs in other organs could serve to modify leaf and canopy architecture in various crops.
APA, Harvard, Vancouver, ISO, and other styles
7

Hansen, Peter J., and Amir Arav. Embryo transfer as a tool for improving fertility of heat-stressed dairy cattle. United States Department of Agriculture, September 2007. http://dx.doi.org/10.32747/2007.7587730.bard.

Full text
Abstract:
The overall objective of the current proposal is to develop procedures to improve the pregnancy rate achieved following transfer of fresh or cryopreserved embryos produced in the laboratory into heat-stress recipients. The overall hypothesis is that pregnancy rate in heat-stressed lactating cows can be improved by use of embryo transfer and that additional gains in pregnancy rate can be achieved through development of procedures to cryopreserve embryos, select embryos most likely to establish and maintain pregnancy after transfer, and to enhance embryo competence for post-transfer survival through manipulation of culture conditions. The original specific objectives were to 1) optimize procedures for cryopreservation (Israel/US), 2) develop procedures for identifying embryos with the greatest potential for development and survival using the remote monitoring system called EmbryoGuard (Israel), 3) perform field trials to test the efficacy of cryopreservation and the EmbryoGuard selection system for improving pregnancy rates in heat-stressed, lactating cows (US/Israel), 4) test whether selection of fresh or frozen-thawed blastocysts based on measurement of group II caspase activity is an effective means of increasing survival after cryopreservation and post-transfer pregnancy rate (US), and 5) identify genes in blastocysts induced by insulin-like growth factor-1 (IGF-1) (US). In addition to these objectives, additional work was carried out to determine additional cellular determinants of embryonic resistance to heat shock. There were several major achievements. Results of one experiment indicated that survival of embryos to freezing could be improved by treating embryos with cytochalasin B to disrupt the cytoskeleton. An additional improvement in the efficacy of embryo transfer for achieving pregnancy in heat-stressed cows follows from the finding that IGF-1 can improve post-transfer survival of in vitro produced embryos in the summer but not winter. Expression of several genes in the blastocyst was regulated by IGF-1 including IGF binding protein-3, desmocollin II, Na/K ATPase, Bax, heat shock protein 70 and IGF-1 receptor. These genes are likely candidates 1) for developing assays for selection of embryos for transfer and 2) as marker genes for improving culture conditions for embryo production. The fact that IGF-1 improved survival of embryos in heat-stressed recipients only is consistent with the hypothesis that IGF-1 confers cellular thermotolerance to bovine embryos. Other experiments confirmed this action of IGF-1. One action of IGF-1, the ability to block heat-shock induced apoptosis, was shown to be mediated through activation of the phosphatidylinositol 3-kinase pathway. Other cellular determinants of resistance of embryos to elevated temperature were identified including redox status of the embryo and the ceramide signaling pathway. Developmental changes in embryonic apoptosis responses in response to heat shock were described and found to include alterations in the capacity of the embryo to undergo caspase-9 and caspase-3 activation as well as events downstream from caspase-3 activation. With the exception of IGF-1, other possible treatments to improve pregnancy rate to embryo transfer were not effective including selection of embryos for caspase activity, treatment of recipients with GnRH.and bilateral transfer of twin embryos. In conclusion, accomplishments achieved during the grant period have resulted in methods for improving post-transfer survival of in vitro produced embryos transferred into heat-stressed cows and have lead to additional avenues for research to increase embryo resistance to elevated temperature and improve survival to cryopreservation. In addition, embryo transfer of vitrified IVF embryos increased significantly the pregnancy rate in repeated breeder cows.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Fibroblast growth factor binding protein 1' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography